Overview
GMED market data
Price History
GMED price chart · 1M
- O
- 77.61
- H
- 78.65
- L
- 77.28
- C
- 78.27
- Vol
- 57,022.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $77.61
- Previous Close
- $78.08
- Day High
- $78.65
- Day Low
- $77.28
- 52 Week High
- $88.86
- 52 Week Low
- $74.48
- 7 Day Return
- -5.77%
- 30 Day Return
- -2.83%
- 90 Day Return
- -0.08%
- 1 Year Return
- +2.10%
- Daily Notional Volume
- $4.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 20.23 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.92 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.99 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 17.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $54.15 – $101.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $10.8B · P/B 2.57 · P/S 3.44.
Company News
10 captured
Here's Why You Should Retain Cencora Stock in Your Portfolio for NowZacks Investment Research ·
Globus Medical Receives CE Mark For Its Excelsius3D Imaging System For Commercial Sale In EU, U.K.Benzinga ·
Here's Why Investors Should Stay Neutral on TDOC Stock for NowZacks Investment Research ·
TMO Stock Could Gain Following the Launch of EMPAD G2 DetectorZacks Investment Research ·
TXG Stock Down Despite Patent Verdict Win Against Parse BiosciencesZacks Investment Research ·
Neogen Surges 102.8% in a Year: What's Driving the Rally?Zacks Investment Research ·
Should You Add Illumina Stock to Your Portfolio Now?Zacks Investment Research ·
Should You Add Teleflex Stock to Your Portfolio Now?Zacks Investment Research ·
Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock UpZacks Investment Research ·